Learn the clinical indicators, risk factors and screening guidelines to properly monitor for this irreversible, rare condition in patients on this drug.
Fifteen years into the anti-VEGF era, protocols are evolving to improve outcomes, reduce treatment burden or both. Here’s what’s new and what’s coming soon.
Intrepid Presents: Innovations and Implementations in Practice Location: Renaissance Newport Beach Program Co-chairs: Nathan Lighthizer, OD, FAAO and John D. Gelles, OD, FIAO, FCLSA Earn 14 LIVE COPE Credits (approval pending)
Establishing a Partnership in the Effective Management of Patients with Diabetic Retinal Disease Location: The Palm Chicago Speakers: Steven Ferrucci, OD, FAAO, and Dilsher Dhoot, MD 7:30–8:30pm CST